Sign in

CIK 0001714899 · Large accelerated filer

Denali Therapeutics Inc.

Sign in to watch
Ticker
DNLI
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
463872213
Phone
(650) 866-8547
Business address
161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA, 94080
  1. 10-Q Report Quarterly Report
  2. 8-K Event Results of operations
  3. 8-K Event Other events
  4. 4 Open-market sale Director sold 1,666 shares at an average $65.13 ($108,510)
  5. 4 Open-market sale COO and Secretary sold 10,000 shares at $76.20 ($762,040)
  6. 4 Open-market sale President and CEO sold 18,333 shares at an average $77.25 ($1,416,300)
  7. 4 Open-market sale Director sold 1,666 shares at an average $70.74 ($117,845)
  8. 4 Open-market sale Director sold 94,378 shares at an average $70.35 ($6,639,523)
  9. 4 Open-market sale COO and Secretary sold 10,000 shares at an average $64.55 ($645,500)
  10. 4 Grant or award Director acquired 2,074 shares (grant or award)
  11. 4 Grant or award Director acquired 2,074 shares (grant or award)
  12. 4 Grant or award Director acquired 2,074 shares (grant or award)
  13. 4 Grant or award Director acquired 2,074 shares (grant or award)
  14. 4 Grant or award Director acquired 2,074 shares (grant or award)
  15. 4 Grant or award Director acquired 2,074 shares (grant or award)
  16. 4 Grant or award Director acquired 2,074 shares (grant or award)
  17. 4 Grant or award Director acquired 2,074 shares (grant or award)
  18. 8-K Event Shareholder vote results
  19. 4 Option exercise Director acquired 3,253 shares (option exercise)
  20. 4 Other disposition Director disposed of 1,000,000 shares (other)

Page 23 of 40 · 789 filings